NewLimit
Group Lead, Immunology
$180K–$240K
South San Francisco +1 · Full-time · Posted Oct 21, 2026
- Location
- South San Francisco
South San Francisco, California, United States - Experience
- Years not specified.
- Education
- Ph.D. in cell biology, immunology, or a related field, or comparable industry experience.
About the job
Leads NewLimit’s Immunology team in developing epigenetic reprogramming therapies to restore youthful function in aged T cells for inflammatory and infectious diseases.
What you'll do
- Lead scientists and research associates developing reprogramming therapies, while contributing to day-to-day execution.
- Develop functional assays and preclinical models, and evaluate payloads to validate targets, select leads, and advance candidates.
- Collaborate across teams on reprogramming interventions and contribute to product decisions, company goals, and the technology platform.
What they ask for
- Ph.D. in cell biology, immunology, or a related field, or comparable industry experience.
- Experience leading a team and managing direct reports.
- Experience with therapeutics development, ideally leading part of discovery or development in immunology, infectious disease, or inflammatory disease.
- Deep knowledge of immunology and lymphocyte biology.
Nice to have
- Direct T cell biology experience, including functional assays, preclinical models, and experimental methods.
- Experience with in vivo nucleic acid delivery, pooled screening, functional genomics, transgenic construct design, iterative product development, aging biology, computational biology, or machine learning.
Pay
$180,000 to $240,000 (base salary; pay period not specified)
Tools
functional genomics, pooled perturbation screening, machine learning models, Single Cell Technology, Epigenetic Editing, Predictive Modeling
AI focus
The company uses machine learning models to investigate epigenetic aging and disease; the role may involve collaboration with the Predictive Modeling team on reprogramming interventions.
Model-written summary · the original posting is authoritative